Literature DB >> 19102374

Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy.

Tadashi Furihata1, Tokihiko Sawada, Junji Kita, Yukihiro Iso, Masato Kato, Kyu Rokkaku, Mitsugi Shimoda, Keiichi Kubota.   

Abstract

BACKGROUND/AIMS: The clinical usefulness of alpha-fetoprotein (AFP) in the management of hepatocellular carcinoma (HCC) remains controversial. This study aimed to assess the prognostic reliability of serum AFP levels per tumor volume (AFP/volume) after curative resection.
METHODOLOGY: A total of 196 patients with HCC were analyzed with reference to serum AFP levels at diagnosis. Clinicopathological data included presence of cirrhosis, indocyanine green retention rate (ICGR15), tumor size and number of HCCs. Tumor volume for HCCs was calculated preoperatively by Computed tomography volumetry, and AFP/volume was calculated by dividing serum AFP level by tumor volume.
RESULTS: No significant correlation between serum AFP levels and presence of cirrhosis or ICGR15 was observed. A significant correlation existed between serum AFP levels and both size (P=0.001, r=0.276) and number (P=0.023, r=0.186) of HCCs. The 5-year survival rates in patients with low (< 200 ng/mL) and high (> or = 200 ng/mL) serum AFP level were 85.0% and 36.0%, respectively. AFP/volume tended to be negatively associated with survival period (p=0.084, r = -0.346), and a significant negative correlation existed between AFP/volume and disease-free survival period (p=0.001, r = -0.347). Median values of AFP/ volume in patients who displayed recurrence by 1 year and 6 months were 11.51 and 20.05, respectively.
CONCLUSIONS: AFP/volume represents a better prognostic indicator for patients with HCC than serum AFP value alone. In particular, patients with AFP/volume > 20.0 are likely to experience recurrence within 6 months after curative hepatectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19102374

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  17 in total

1.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

Review 2.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

3.  Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence?

Authors:  Chung-Bao Hsieh; Teng-Wei Chen; Chi-Ming Chu; Heng-Cheng Chu; Cheng-Ping Yu; Kuo-Piao Chung
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

4.  GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.

Authors:  De-Yong Gao; Yun Ling; Xiao-Li Lou; Ying-Ying Wang; Liang-Ming Liu
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

5.  Serum alpha-fetoprotein level per total tumor volume as a predictor of recurrence of hepatocellular carcinoma after resection.

Authors:  Yeshika Sharma; Michael J Weaver; Daniel R Ludwig; Kathryn Fowler; Neeta Vachharajani; William C Chapman; Jeffrey S Crippin
Journal:  Surgery       Date:  2017-12-25       Impact factor: 3.982

6.  HCC in older patients.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Dig Dis Sci       Date:  2010-03-18       Impact factor: 3.199

7.  Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Sevil Uygun Ilikhan; Muammer Bilici; Hatice Sahin; Ayşe Semra Demir Akca; Murat Can; Ibrahim Ilker Oz; Berrak Guven; M Cagatay Buyukuysal; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

8.  Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses.

Authors:  L Renee Ruhaak; Sandra L Taylor; Suzanne Miyamoto; Karen Kelly; Gary S Leiserowitz; David Gandara; Carlito B Lebrilla; Kyoungmi Kim
Journal:  Anal Bioanal Chem       Date:  2013-03-23       Impact factor: 4.142

Review 9.  The evolving role of mass spectrometry in cancer biomarker discovery.

Authors:  Pei Wang; Jeffrey R Whiteaker; Amanda G Paulovich
Journal:  Cancer Biol Ther       Date:  2009-06-06       Impact factor: 4.742

10.  IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.

Authors:  Shuai Hu; Xiaofeng Wu; Bo Zhou; Zhenchao Xu; Jianjie Qin; Hao Lu; Ling Lv; Yun Gao; Lei Deng; Jie Yin; Guoqiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-20       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.